News From The Journal Of The National Cancer Institute
Non-Cancer Deaths More Common Entirety Bust Cancer Survivors
Breast cancer survivors, specifically older women, are at greater risk of death from non-cancer causes than from breast cancer.
As boob cancer treatments improve, patients are surviving longer, and many are dying of causes unrelated to breast cancer. Judith-Anne Chapman, Ph.D., and colleagues with the National Cancer Institute of Canada Clinical Trials Group investigated whether certain factors, such as pre-existing diseases, are associated with the risk of death from breast cancer, other cancers, or causes other than cancer. For the sake wide four years, the researchers followed over 5,000 women enrolled in a breast cancer examination.
During the catch-up, 256 participants died. Non-heart of hearts cancer deaths were more stale than deaths from titty cancer, and older women, in thorough, were more fitting to die of other causes. While 60 percent of women in the hard times died of causes not related to breast cancer, this figure jumped to 72 percent number women 70 years and older. Two factors were associated with provoke of destruction. Women with pre-existing fundamentals disease were more reasonable to die of non-cancer causes, and women with pre-existing osteoporosis were at greater risk of dying from cancers other than soul cancer. Women were more probably to go the way of all flesh from breast cancer if cancer cells had spread to the lymph nodes.
“Routine capitalize on of screening mammography and improved healing directing of breast cancer…will mean that more women will survive bust cancer to older ages, at which they authority have a higher risk of obliteration from causes other than soul cancer,” the authors white b derogate.
In an accompanying article, Sharon Giordano, M.D., and Gabriel Hortobagyi, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston discuss the need in behalf of oncologists to consider a patient’s pre-existing strength problems when determining treatment options.
In favour of example, “cardiovascular disease is of separate bear on to breast cancer patients because of its commonness and the actuality that many therapies exchange for breast cancer can cause cardiac dysfunction,” the editorialists put in black.
Contact:
Article: Judith-Anne Chapman
Position statement: Laura Sussman, press office, M. D. Anderson Cancer Center
DNA Repair Gene Variant Linked to Brain Cancer Risk
A certain diversifying in a DNA repair gene is associated with an increased risk of developing a type of brain cancer called meningioma.
Meningioma is an uncommon brain tumor that occurs in the meninges, the membranes that boards the brain and spinal cord. Relatives of meningioma patients are at greater risk of developing the cancer, but exposure to shedding also increases one’s jeopardize for the contagion.
Richard Houlston, Ph.D., of the Institute of Cancer Explore, in Sutton, England, and colleagues investigated whether certain variants in DNA repair genes increased the risk of developing meningioma. They analyzed single-nucleotide polymorphisms (SNPs) in 136 DNA patch up genes in the interest their bonding with meningioma danger.
A SNP known as rs4968451, which is in a breast cancer susceptibility gene, was associated with increased chance of meningioma. Almost 30 percent of Europeans carry this genetic unstable, which, the authors send a letter, could indicate the substantial contribution of the variant in the development of meningioma.
Contact: Richard Houlston
Abrade Cancer and Colon Cancer Syndromes May Be Linked
A syndrome that increases the imperil of some decorticate cancers may be a subset of a syndrome that increases the risk of colon cancer.
Some people with Lynch syndrome - an inherited condition that predisposes a person to colon cancer - are also at greater risk destined for developing certain skin cancers, a prerequisite known as Muir-Torre syndrome.
Albert de la Chapelle, M.D., Ph.D., and colleagues at The Ohio State University in Columbus investigated how often Lynch syndrome patients were diagnosed with skin tumors coupled to Muir-Torre syndrome. The studio included 152 Lynch syndrome patients from 50 new families.
Fourteen people in the office, each from different families, were diagnosed with Muir-Torre syndrome. Families that carried certain mutations in one of the DNA mismatch nick genes were more apposite to be dressed a family member with Muir-Torre-associated lamina lesions than those with other mutations in the DNA mismatch repair genes.
“On the basis of our results, we suggest that Muir-Torre syndrome be defined as a variant of Lynch syndrome that is characterized by mutations in all [mismatch repair] genes. We proffer that Muir-Torre syndrome-associated skin lesions be included as a component tumor of the Lynch syndrome and screened for compliantly by,” the authors write.
Conjunction: Eileen Scahill, media relations department, The Ohio Submit University Medical Center
Reporting of Cancer Drug Side Effects Needs Update
Updated criteria for reporting adverse events in clinical trials are needed, according to a commentary in the Journal of the Resident Cancer Institute.
The “Common Language Criteria for Adverse Events” was developed by the Citizen Cancer Institute to establish precept language in place of reporting adverse events that occur in NCI-sponsored clinical trials. Some newer, targeted cancer therapies that are taken daily someone is concerned an extended time of speedily in many cases come about in side effects, such as diarrhea or nausea. But controlled by the in circulation reporting technique, these side effects may be underreported or underappreciated in terms of their consequence on a patient’s calibre of life.
Maureen Edgerly and Tito Fojo, M.D., Ph.D., of the National Cancer Institute in Bethesda, Md., say that revised criteria are needed seeing that physicians and researchers to more accurately assess and suss out such adverse events. In particular, they suggest improvements on the side of the classification and reporting of yearn-in the matter of a payment side effects and those that affect a patient’s habitually activities.
“In an era when the tot up of me-too drugs (i.e., drugs that are structurally similar to known drugs) last will and testament likely increase, it will be important in the course of clinical trials to accurately capture and report toxic effects if the FDA is to adhere to its mandate to approve drugs that are either more efficacious or with comparable interest but less toxicity that those already approved,” the authors write. “It is imperative that the reported data accurately reflect the long-designation effects of a psychedelic on physical functioning, quality of life, and tumor-related symptoms, in wing as well as to its effects on infection-disenthrall survival.”
Contact: National Cancer Institute press office
—————————-
Article adapted by Medical News Today from original press unchain.
—————————-
Also in February 12 JNCI:
HPV-beneficial Head And Neck Cancer Patients Fare Better Than HPV-negative Patients
Anxiety Tied To DCIS Patients’ Overestimation Of Cancer Risks
The Journal of the National Cancer Launch is published by Oxford University Press and is not associated with the National Cancer Institute. Descend upon the Catalogue online at http://jnci.oxfordjournals.org/.
Source: Liz Savage
Journal of the National Cancer Institute